Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: Interim outcomes of a prospective clinical trial.

Bowden P, See AW, Frydenberg M, Haxhimolla H, Costello AJ, Moon D, Ruljancich P, Grummet J, Crosthwaite A, Pranavan G, Peters JS, So K, Gwini SM, McKenzie DP, Nolan S, Smyth LML, Everitt C.

Int J Cancer. 2019 Jun 14. doi: 10.1002/ijc.32509. [Epub ahead of print]

PMID:
31199504
2.

Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.

Kneebone A, Hruby G, Ainsworth H, Byrne K, Brown C, Guo L, Guminski A, Eade T.

Eur Urol Oncol. 2018 Dec;1(6):531-537. doi: 10.1016/j.euo.2018.04.017. Epub 2018 May 23.

PMID:
31158100
3.

Stereotactic body radiotherapy for castration-sensitive prostate cancer bone oligometastases.

Fanetti G, Marvaso G, Ciardo D, Rese A, Ricotti R, Rondi E, Comi S, Cattani F, Zerini D, Fodor C, de Cobelli O, Orecchia R, Jereczek-Fossa BA.

Med Oncol. 2018 Apr 18;35(5):75. doi: 10.1007/s12032-018-1137-0.

PMID:
29671075
4.

Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT).

Habl G, Straube C, Schiller K, Duma MN, Oechsner M, Kessel KA, Eiber M, Schwaiger M, Kübler H, Gschwend JE, Combs SE.

BMC Cancer. 2017 May 22;17(1):361. doi: 10.1186/s12885-017-3341-2.

5.

Benefits of Using Stereotactic Body Radiotherapy in Patients With Metachronous Oligometastases of Hormone-Sensitive Prostate Cancer Detected by [18F]fluoromethylcholine PET/CT.

Bouman-Wammes EW, van Dodewaard-De Jong JM, Dahele M, Cysouw MCF, Hoekstra OS, van Moorselaar RJA, Piet MAH, Verberne HJ, Bins AD, Verheul HMW, Slotman BJ, Oprea-Lager DE, Van den Eertwegh AJM.

Clin Genitourin Cancer. 2017 Oct;15(5):e773-e782. doi: 10.1016/j.clgc.2017.03.009. Epub 2017 Mar 29.

PMID:
28462855
6.

Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer.

Ahmed KA, Barney BM, Davis BJ, Park SS, Kwon ED, Olivier KR.

Front Oncol. 2013 Jan 22;2:215. doi: 10.3389/fonc.2012.00215. eCollection 2012.

7.

Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence.

Decaestecker K, De Meerleer G, Lambert B, Delrue L, Fonteyne V, Claeys T, De Vos F, Huysse W, Hautekiet A, Maes G, Ost P.

Radiat Oncol. 2014 Jun 12;9:135. doi: 10.1186/1748-717X-9-135.

8.

Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial.

Siva S, Bressel M, Murphy DG, Shaw M, Chander S, Violet J, Tai KH, Udovicich C, Lim A, Selbie L, Hofman MS, Kron T, Moon D, Goad J, Lawrentschuk N, Foroudi F.

Eur Urol. 2018 Oct;74(4):455-462. doi: 10.1016/j.eururo.2018.06.004. Epub 2018 Jun 29.

PMID:
30227924
9.

Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.

Battaglia A, De Meerleer G, Tosco L, Moris L, Van den Broeck T, Devos G, Everaerts W, Joniau S.

Eur Urol Oncol. 2019 Mar;2(2):174-188. doi: 10.1016/j.euo.2018.09.005. Epub 2018 Oct 9. Review.

PMID:
31017094
10.

Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience.

Chen LN, Suy S, Uhm S, Oermann EK, Ju AW, Chen V, Hanscom HN, Laing S, Kim JS, Lei S, Batipps GP, Kowalczyk K, Bandi G, Pahira J, McGeagh KG, Collins BT, Krishnan P, Dawson NA, Taylor KL, Dritschilo A, Lynch JH, Collins SP.

Radiat Oncol. 2013 Mar 13;8:58. doi: 10.1186/1748-717X-8-58.

11.

SBRT: An Opportunity to Improve Quality of Life for Oligometastatic Prostate Cancer.

Azzam G, Lanciano R, Arrigo S, Lamond J, Ding W, Yang J, Hanlon A, Good M, Brady L.

Front Oncol. 2015 May 5;5:101. doi: 10.3389/fonc.2015.00101. eCollection 2015.

12.

Exploring All Avenues for Radiotherapy in Oligorecurrent Prostate Cancer Disease Limited to Lymph Nodes: A Systematic Review of the Role of Stereotactic Body Radiotherapy.

Ponti E, Lancia A, Ost P, Trippa F, Triggiani L, Detti B, Ingrosso G.

Eur Urol Focus. 2017 Dec;3(6):538-544. doi: 10.1016/j.euf.2017.07.006. Epub 2017 Aug 8.

PMID:
28801240
13.

Salvage Stereotactic Body Radiotherapy for Isolated Lymph Node Recurrent Prostate Cancer: Single Institution Series of 94 Consecutive Patients and 124 Lymph Nodes.

Jereczek-Fossa BA, Fanetti G, Fodor C, Ciardo D, Santoro L, Francia CM, Muto M, Surgo A, Zerini D, Marvaso G, Timon G, Romanelli P, Rondi E, Comi S, Cattani F, Golino F, Mazza S, Matei DV, Ferro M, Musi G, Nolè F, de Cobelli O, Ost P, Orecchia R.

Clin Genitourin Cancer. 2017 Aug;15(4):e623-e632. doi: 10.1016/j.clgc.2017.01.004. Epub 2017 Jan 11.

PMID:
28185875
15.
16.

A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy.

Bolzicco G, Favretto MS, Satariano N, Scremin E, Tambone C, Tasca A.

BMC Urol. 2013 Oct 17;13:49. doi: 10.1186/1471-2490-13-49.

17.
18.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
19.

Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer.

Muldermans JL, Romak LB, Kwon ED, Park SS, Olivier KR.

Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):696-702. doi: 10.1016/j.ijrobp.2016.01.032. Epub 2016 Jan 29.

20.

Supplemental Content

Support Center